Zydus plans launch of semaglutide generic in reusable pen form

Zydus Lifesciences is set to launch a generic version of the weight-loss injection semaglutide next month. The drug will be available under brand names Semaglyn, Mashema, and Altreme. Zydus will offer a unique reusable pen for easier dosage adjustment. This move aims to simplify treatment for patients managing Type 2 diabetes and obesity.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fEWJ2gU
via IFTTT

Read More

GST department initiates inspection and search ops at Lupin's office

Maharashtra's Goods & Services Tax Department has initiated inspection and search proceedings at Lupin's registered office. The pharmaceutical giant stated that these actions will not impact its financials, operations, or other activities. Lupin recently reported strong Q3 FY26 growth, with highest-ever US sales and double-digit growth in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/raeUq9M
via IFTTT

Read More

India’s weight-loss drugs to get cheaper as semaglutide patent expires

Affordable generic versions of popular weight-loss drugs Wegovy and Ozempic are set to launch in India. This follows the patent expiry of semaglutide, the key ingredient. Several Indian pharmaceutical companies are preparing for a March 21 launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GcepZab
via IFTTT

Read More

Dr Reddy's gearing up for March debut of generic semaglutide Obeda, sources say

Dr Reddy's Laboratories is poised to launch its generic semaglutide injection, potentially named Obeda, in India by March. This move anticipates the March 2026 patent expiry for the active ingredient in Novo Nordisk's Ozempic and Wegovy. The Indian drugmaker plans competitive pricing, aiming to capture a significant share of the growing diabetes and obesity market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rkOETu6
via IFTTT

Read More

Merck & Co to create a separate cancer unit as patent cliff looms

Merck & Co is restructuring by splitting its drug division into two separate businesses. The change is designed to spotlight its fastest-growing medicines as the blockbuster cancer therapy Keytruda nears patent expiration. The company plans to emphasize newer products, including a pneumonia vaccine and a treatment for lung disease, as key drivers of its next growth phase.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GvSQanm
via IFTTT

Read More

Drug regulator cracks down hard on non-compliant cough syrup makers

Authorities are cracking down on hundreds of cough syrup manufacturers failing quality checks. This action follows tragic deaths linked to toxic ingredients. Inspections are ongoing, with strict measures like unit closures and license cancellations being implemented. The drug regulator aims to eliminate substandard cough syrup production. Manufacturers must adhere to new quality standards or face closure.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lFP34rK
via IFTTT

Read More

Government urges pharma sector to anchor global supply chains via quality, innovation

Union Minister J P Nadda urged India's pharmaceutical industry to lead global supply chains with quality and innovation. India is embracing new technologies for disease detection and diagnostics. Initiatives like Biopharma Shakti and PRIP are boosting manufacturing and research. The nation is committed to regulatory excellence and aligning with global standards. A quality-first approach is key to sustained global competitiveness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Zd4mrz
via IFTTT

Read More